Clofibrate, pirinixil (BR 931) and WY-14,643 do not affect body cholesterol in Sprague-Dawley rats

Cholesterol levels in plasma and different tissues were determined in Sprague-Dawley male rats, on standard and cholesterol-cholic acid enriched diets, after short term treatment with the absorbable hypolipidemic agents, clofibrate, WY-14,643 and Pirinixil (BR 931). The objective of the study was to evaluate the mode of action of these drugs in decreasing plasma Cholesterol, be it by increased tissue mobilization, or by redistribution from plasma to tissues. After one or two weeks on a standard diet, none of the three agents significantly affected total body Cholesterol stores. In spite of the liver enlargement induced by all three, in no case was total liver Cholesterol significantly raised. Only clofibrate significantly increased colonic Cholesterol concentrations. On a cholesterol-cholic acid regimen, some Cholesterol mobilization was noted with all three drugs. However, only Pirinixil significantly reduced total liver Cholesterol as well as the estimated total body Cholesterol. A parallel effect of diet and drugs on plasma and body Cholesterol pools is not constantly observed. In the examined rat model, clofibrate and two chemically unrelated compounds with a probably similar mechanism of action, markedly reduce plasma Cholesterol levels while not affecting or decreasing total body Cholesterol stores.